Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance

Reuters03-28

Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance

Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE (icotrokinra) were presented at 2026 American Academy of Dermatology annual meeting.
Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.
Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.
ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.
Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603281005ACCESSWRNAPR_____1152808) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622738492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622738492","market":"nz","top_or_hot":-1,"title":"Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE (icotrokinra) were presented at 2026 American Academy of Dermatology annual meeting.\n        </li>\n<li>\n          Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.\n        </li>\n<li>\n          Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.\n        </li>\n<li>\n          ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.\n        </li>\n<li>\n          Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PTGX\">Protagonist Therapeutics Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603281005ACCESSWRNAPR_____1152808) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE (icotrokinra) were presented at 2026 American Academy of Dermatology annual meeting.\n        </li>\n<li>\n          Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.\n        </li>\n<li>\n          Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.\n        </li>\n<li>\n          ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.\n        </li>\n<li>\n          Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PTGX\">Protagonist Therapeutics Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603281005ACCESSWRNAPR_____1152808) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL6XV6GV:1","article_id":"2622738492","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622738492","pubTimestamp":1774706729,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE  were presented at 2026 American Academy of Dermatology annual meeting.Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc","BK4139":"生物科技"},"translate_title":"主角称Icotyde 3期一年牛皮癣数据显示持久皮肤清除","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":0.9},"content_text":"Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance\n    \n\n\n          Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE (icotrokinra) were presented at 2026 American Academy of Dermatology annual meeting.\n        \n\n          Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.\n        \n\n          Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.\n        \n\n          ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.\n        \n\n          Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603281005ACCESSWRNAPR_____1152808) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622738492","isCrawlerRequest":true}